Unexpectedly, Immunotherapy Response Linked to Low TMB in rGMB Unexpectedly, Immunotherapy Response Linked to Low TMB in rGMB
In contrast to what has been seen in other tumor types, recurrent glioblastoma (rGMB) appears to respond better to immunotherapy when tumor mutational burden (TMB) is low.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 19, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

New study identifies opposite roles of sugars and fat on cellular immunotherapy of cancer
(Instituto de Medicina Molecular) The team led by Bruno Silva Santos, Principal Investigator iMM, discovered that the functions of a subtype of white blood cells - gamma delta T cells - are regulated by metabolic resources, namely sugars and fat. The results now published in the scientific journal Nature Immunology, open new avenues for the use of sugar metabolism in gamma-delta T cells as an effective tool in cellular immunotherapy of cancer, in addition to building further on the concept that high cholesterol levels are a barrier to its effectiveness. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 18, 2021 Category: Cancer & Oncology Source Type: news

Actinium, Astellas to create actinium-225 radiotherapies
Immunotherapy technology developer Actinium Pharmaceuticals will work with...Read more on AuntMinnie.comRelated Reading: GE purchases expanded rights to Rapiscan stress agent Actinium studied as potential anticancer drug Zevacor signs on as manufacturing partner for Actinium SNMMI: PET/MR up for challenge of detecting CAD (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - January 13, 2021 Category: Radiology Source Type: news

Recurrent GBM brain tumors with few mutations respond best to immunotherapy
(Duke University Medical Center) New insights from a team led by Duke's Preston Robert Tisch Brain Tumor Center provide potential answers about why immunotherapies have limited success against brain tumors. The team found that recurring glioblastoma tumors with very few mutations are far more vulnerable to immunotherapies than similar tumors with an abundance of mutations. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 13, 2021 Category: International Medicine & Public Health Source Type: news

MD Anderson and UroGen Pharma announce strategic research collaboration to advance investigational treatment for high-grade bladder cancer
(University of Texas M. D. Anderson Cancer Center) MD Anderson and UroGen today announced a strategic three-year collaboration agreement to advance combination immunotherapy, delivered directly into the bladder, for the treatment of high-grade non-muscle invasive bladder cancer. The collaboration will work through MD Anderson's immunotherapy platform to design pre-clinical and clinical studies. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 13, 2021 Category: International Medicine & Public Health Source Type: news

Strategic-collaboration-with-EnaraBio
Boehringer Ingelheim and Enara Bio Enter Strategic Collaboration and Licensing Agreement to Discover Novel Shared Antigens for Cancer Immunotherapies  Collaboration focuses on up to three types of lung and gastrointestinal (GI) cancersLatest in a series of strategic acquisitions and partnerships that strengthens Boehringer Ingelheim ’s position in the cancer vaccine and T-cell engager spacesAgreement and partnership with Boehringer Ingelheim provides additional validation of Enara Bio ’s  EDAPT™ platform and Dark Antigen™ discovery work and supports ongoing cell therapy based therapeutic a...
Source: Boehringer Ingelheim Corporate News - January 12, 2021 Category: Research Source Type: news

New humanized mouse model provides insight into immunotherapy resistance
(The Wistar Institute) Wistar scientists have created an advanced humanized immune system mouse model that allows them to examine resistance to immune checkpoint blockade therapies in melanoma. It has revealed a central role for mast cells. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 12, 2021 Category: International Medicine & Public Health Source Type: news

Sanofi acquires immunotherapy biotech Kymab
French group also weighs possibility of manufacturing rival Covid-19 vaccines (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - January 11, 2021 Category: Pharmaceuticals Source Type: news

mRNA Technology Gave Us the First COVID-19 Vaccines. It Could Also Upend the Drug Industry
“No!” The doctor snapped. “Look at me!” I had been staring her in the eyes, as she had ordered, but when a doctor on my other side began jabbing me with a needle, I started to turn my head. “Don’t look at it,” the first doctor said. I obeyed. This was in early August in New Orleans, where I had signed up to be a participant in the clinical trial for the Pfizer-BioNTech COVID-19 vaccine. It was a blind study, which meant I was not supposed to know whether I had gotten the placebo or the real vaccine. I asked the doctor if I would really been able to tell by looking at the syringe. &...
Source: TIME: Health - January 11, 2021 Category: Consumer Health News Authors: Walter Isaacson Tags: Uncategorized COVID-19 feature Magazine Source Type: news

mRNA Technology Gave Us the First COVID-19 Vaccines. It Could Also Upend the Drug Industry
“No!” The doctor snapped. “Look at me!” I had been staring her in the eyes, as she had ordered, but when a doctor on my other side began jabbing me with a needle, I started to turn my head. “Don’t look at it,” the first doctor said. I obeyed. This was in early August in New Orleans, where I had signed up to be a participant in the clinical trial for the Pfizer-BioNTech COVID-19 vaccine. It was a blind study, which meant I was not supposed to know whether I had gotten the placebo or the real vaccine. I asked the doctor if I would really been able to tell by looking at the syringe. &...
Source: TIME: Science - January 11, 2021 Category: Science Authors: Walter Isaacson Tags: Uncategorized COVID-19 feature Magazine Source Type: news

'Invisible' stem cells evade natural killer cells using immune 'off-switch'
(University of California - San Francisco) UC San Francisco scientists have discovered a new way to control the immune system's 'natural killer' (NK) cells, a finding with implications for novel cell therapies and tissue implants that can evade immune rejection. The findings could also be used to enhance the ability of cancer immunotherapies to detect and destroy lurking tumors. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 8, 2021 Category: Cancer & Oncology Source Type: news

Cancer research biotech ImmunSYS files for bankruptcy
The company is a clinical-stage biopharmaceutical firm focused on developing new cancer immunotherapy treatments. (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - January 7, 2021 Category: Health Management Authors: Ashley Portero Source Type: news

Statins May Give Boost to Mesothelioma Immunotherapy Drugs
This study, which included both patients with pleural mesothelioma and with advanced non-small cell lung cancer, found a potential synergy with the immunotherapy drugs. Opdivo and Keytruda, generically called nivolumab and pembrolizumab, respectively, are known as PD-1 inhibitors, drugs that restrict a protein from stopping immune response to cancer cells. “Statins may lead to prolonged antigen retention on cell membrane and strengthen antigen presentation to T cells, thus suggesting a potential synergy with PD-1 inhibitors,” the authors wrote. “The anti-tumor effect of statins might be attributed to an i...
Source: Asbestos and Mesothelioma News - January 7, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Carisma Therapeutics raises $47M in Series B round as company reaches 'key inflection point'
The immunotherapy company in screening cancer patients for its first human drug study. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - January 7, 2021 Category: American Health Authors: John George Source Type: news

Gut microbe may promote breast cancers
(Johns Hopkins Medicine) A microbe found in the colon and commonly associated with the development of colitis and colon cancer also may play a role in the development of some breast cancers, according to new research from investigators with the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 6, 2021 Category: Cancer & Oncology Source Type: news

Scientists create ON-OFF switches to control CAR T cell activity
(Dana-Farber Cancer Institute) Scientists at Dana-Farber Cancer Institute and Mass General Cancer Center have created molecular ON-OFF switches to regulate the activity of CAR T cells, a potent form of cell-based immunotherapy that has had dramatic success in treating some advanced cancers, but which pose a significant risk of toxic side effects. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 6, 2021 Category: Cancer & Oncology Source Type: news

COVID Vaccine Side Effects More Common After 2nd Dose, Says Dr. Mallika Marshall
cbsoptanon.onScriptsReady(function(cmp){cmp.ot.targetingAllowed(function(a){if(a) AnvatoPlayer("p0").init({"mcp":"cbs","width":"100%","height":"100%","video":"5173296","autoplay":false,"titleVisible":false,"accessKey":"EZqvRyKE7qmqDflDPXIw6U7kKZEA0Vx7","accessControl":{"preview":false},"pInstance":"p0","plugins":{"heartbeat":{"account":"cbslocal-global-unified","publisherId":"cbslocal","jobId...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - January 6, 2021 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Covid-19 Boston, MA Health Healthcare Status Syndicated CBSN Boston Syndicated Local Coronavirus Coronavirus Vaccine Dr. Mallika Marshall Kristina Rex Source Type: news

Roche ’s novel anti-TIGIT tiragolumab granted FDA Breakthrough Therapy Designation in combination with Tecentriq for PD-L1-high non-small cell lung cancer
Basel, 5 January 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that tiragolumab, a novel cancer immunotherapy designed to bind to TIGIT, has been granted Breakthrough Therapy Designation (BTD) by the US Food and Drug Administration (FDA), in combination with Tecentriq ® (atezolizumab) for the first-line treatment of people with metastatic non-small cell lung cancer (NSCLC) whose tumours have high PD-L1 expression with no EGFR or ALK genomic tumour aberrations. Tiragolumab is the first anti-TIGIT molecule to be granted BTD from the FDA, and the designation is bas ed on randomised data from the phase II CITYS...
Source: Roche Investor Update - January 5, 2021 Category: Pharmaceuticals Source Type: news

Roche ’s novel anti-TIGIT tiragolumab granted FDA Breakthrough Therapy Designation in combination with Tecentriq for PD-L1-high non-small cell lung cancer
Basel, 5 January 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that tiragolumab, a novel cancer immunotherapy designed to bind to TIGIT, has been granted Breakthrough Therapy Designation (BTD) by the US Food and Drug Administration (FDA), in combination with Tecentriq ® (atezolizumab) for the first-line treatment of people with metastatic non-small cell lung cancer (NSCLC) whose tumours have high PD-L1 expression with no EGFR or ALK genomic tumour aberrations. Tiragolumab is the first anti-TIGIT molecule to be granted BTD from the FDA, and the designation is bas ed on randomised data from the phase II CITYS...
Source: Roche Media News - January 5, 2021 Category: Pharmaceuticals Source Type: news

Study explains why patients with cancer spread to the liver have worse outcomes
(Michigan Medicine - University of Michigan) A new study finds that tumors in the liver siphon off critical immune cells, rendering immunotherapy ineffective. But coupling immunotherapy with radiotherapy to the liver in mice restored the immune cell function and led to better outcomes. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 4, 2021 Category: Cancer & Oncology Source Type: news

Study: Modified immunotherapy may work in advanced breast cancer
Women with advanced breast cancer may have a new weapon in their fight against the disease -- a modified form of CAR-T based immunotherapy. (Source: Health News - UPI.com)
Source: Health News - UPI.com - December 31, 2020 Category: Consumer Health News Source Type: news

Study points the way to boost immunotherapy against breast cancer, other solid tumors
(UNC Lineberger Comprehensive Cancer Center) UNC Lineberger Comprehensive Cancer Center researchers report that adding a small molecule to a chimeric antigen receptor-T (CAR-T) cell therapy can help immune system T cells to effectively attack solid tumors, such as breast cancers. The boost helps recruit more immune cells into battle at the tumor site, according to the study published in theJournal of Experimental Medicine. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 31, 2020 Category: International Medicine & Public Health Source Type: news

Combined approach could boost breast cancer immunotherapy, study suggests
(Rockefeller University Press) Activating an immune signaling pathway best known for fighting viral and bacterial infections can boost the ability of genetically engineered T cells to eradicate breast cancer in mice, according to a new study by researchers at the University of North Carolina. The study, to be published December 31 in theJournal of Experimental Medicine (JEM), suggests that CAR T cells, which are already used to treat certain blood cancers in humans, may also be successful against solid tumors if combined with other immunotherapeutic approaches. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 31, 2020 Category: International Medicine & Public Health Source Type: news

Highlights in Metastatic Breast Cancer From SABCS 2020 Highlights in Metastatic Breast Cancer From SABCS 2020
From SABCS 2020, Dr Harold Burstein reports on advances for patients with HER2- metastatic breast cancer, including updates on immunotherapy and promising results for a novel oral taxane.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 30, 2020 Category: Consumer Health News Tags: Hematology-Oncology ReCAP Source Type: news

AIVITA Biomedical Closes $25 Million Financing Round
IRVINE, Calif., Dec. 29, 2020 -- (Healthcare Sales & Marketing Network) -- AIVITA Biomedical, Inc., a private biotechnology company developing personalized vaccines for the treatment of cancer and prevention of COVID-19, has closed its Series B-2 financin... Biopharmaceuticals, Oncology, Venture Capital AIVITA Biomedical, cancer vaccine, immunotherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 29, 2020 Category: Pharmaceuticals Source Type: news

University of Chicago cancer center names Dr. Adekunle “Kunle” Odunsi as new director
Roswell Park Comprehensive Cancer Center is losing its No. 2 executive to a Chicago cancer hospital. Dr. Adekunle “Kunle” Odunsi has been named director of University of Chicago Medicine Comprehensive Cancer Center, effective March 1. Odunsi, who joined Roswell Park in 2001, has served as deputy director since 2015, as well as chairman of the hospital’s department of gynecologic oncology and executive director of the Center for Immunotherapy. A gynecologic oncologist, Odunsi specializes… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 24, 2020 Category: Pharmaceuticals Authors: Tracey Drury Source Type: news

University of Chicago cancer center names Dr. Adekunle “Kunle” Odunsi as new director
Roswell Park Comprehensive Cancer Center is losing its No. 2 executive to a Chicago cancer hospital. Dr. Adekunle “Kunle” Odunsi has been named director of University of Chicago Medicine Comprehensive Cancer Center, effective March 1. Odunsi, who joined Roswell Park in 2001, has served as deputy director since 2015, as well as chairman of the hospital’s department of gynecologic oncology and executive director of the Center for Immunotherapy. A gynecologic oncologist, Odunsi specializes… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 24, 2020 Category: Biotechnology Authors: Tracey Drury Source Type: news

Dexamethasone May Nix Immunotherapy Benefit in Glioblastoma Dexamethasone May Nix Immunotherapy Benefit in Glioblastoma
Investigators found that baseline dexamethasone use was associated with poor overall survival (OS) in glioblastoma patients receiving anti –PD-1 or anti–PD-L1 therapy.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 23, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Arthritis drug may treat immunotherapy-related heart complication
(Vanderbilt University Medical Center) A drug typically prescribed for rheumatoid arthritis may also be effective in treating a rare but potentially deadly heart complication some cancer patients experience after taking immunotherapies, according to a study published in Cancer Discovery and co-led by investigators at Vanderbilt University Medical Center (VUMC). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 21, 2020 Category: International Medicine & Public Health Source Type: news

Diseased cell fragments burst from pockets in immune cells to activate response
(The Francis Crick Institute) Researchers at the Francis Crick Institute have uncovered an important process in how our immune system detects signs of disease and activates a protective response. This understanding could improve efforts to find new and effective immunotherapy treatments for diseases like cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 21, 2020 Category: International Medicine & Public Health Source Type: news

Mayo Clinic Q & amp;A podcast: Study finds unique form of immunosuppression caused by brain cancer
The latest direction in cancer treatment has been toward potential cancer vaccines and immunotherapies. As these therapies become standard, continued research is important to understand how the body interacts with these treatments. A recent Mayo Clinic study found a unique form of immunosuppression caused by brain cancer that could inhibit the effectiveness of cancer vaccines [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - December 19, 2020 Category: Databases & Libraries Source Type: news

Breast cancer study uncovers how macrophages may contribute to a therapeutic weak spot
(Brigham and Women's Hospital) Clinical trials have investigated pairing PARP inhibitor therapy with immunotherapy. Researchers are already looking ahead for ways to get even more benefit from PARP inhibitors plus checkpoint inhibitors in breast cancer patients. Investigators found macrophage-mediated immune suppression to be the weak spot of PARP inhibition treatment. Findings are published inNature Cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 18, 2020 Category: International Medicine & Public Health Source Type: news

Society for Immunotherapy of Cancer Publishes Clinical Practice...
The Society for Immunotherapy of Cancer (SITC), the world’s leading member-driven organization dedicated solely to cancer immunotherapy, is pleased to announce the publication of a clinical practice...(PRWeb December 18, 2020)Read the full story at https://www.prweb.com/releases/society_for_immunotherapy_of_cancer_publishes_clinical_practice_guideline_on_immune_effector_cell_related_adverse_events/prweb17624000.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - December 18, 2020 Category: Pharmaceuticals Source Type: news

Scientists unlock promising key to preventing cancer relapse after immunotherapy
(The Mount Sinai Hospital / Mount Sinai School of Medicine) The researchers discovered that cancer immunotherapies that make use of immune system cells such as T cells and CAR-T cells kill not only tumor cells that express the drugs' target, but also adjacent tumor cells that lack the targets, because of the presence of fas. This process, known as bystander killing, can be made more effective by adding therapeutics that turn off the regulation of fas proteins, the researchers said. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 17, 2020 Category: International Medicine & Public Health Source Type: news

Errant DNA boosts immunotherapy effectiveness
(UT Southwestern Medical Center) DALLAS - Dec. 17, 2020 - DNA that ends up where it doesn't belong in cancer cells can unleash an immune response that makes tumors more susceptible to immunotherapy, the results of two UT Southwestern studies indicate. The findings, published online today inCancer Cell, suggest that delivering radiation - which triggers DNA release from cells - before immunotherapy could be an effective way to fight cancers that are challenging to treat. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 17, 2020 Category: International Medicine & Public Health Source Type: news

SU2C research leads to FDA approval of new first-line treatment for colorectal cancer
(Stand Up To Cancer) The FDA recently approved the immunotherapy drug pembrolizumab as a first-line treatment for patients with certain types of advanced colorectal cancer. This is the 9th FDA approval supported by Stand Up To Cancer ® (SU2C) research. Patients newly diagnosed with advanced or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer previously would have been prescribed pembrolizumab only after exhausting standard chemotherapy treatments. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 16, 2020 Category: Cancer & Oncology Source Type: news

Olathe biotech startup TVAX clears FDA hurdles for treatments to combat deadly cancers
In partnership with a California company, TVAX Biomedical Inc. developed an immunotherapy treatment for pancreatic cancer. (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - December 15, 2020 Category: Health Management Authors: Ellen Cagle Source Type: news

Olathe biotech startup TVAX clears FDA hurdles for treatments to combat deadly cancers
In partnership with a California company, TVAX Biomedical Inc. developed an immunotherapy treatment for pancreatic cancer. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 15, 2020 Category: Biotechnology Authors: Ellen Cagle Source Type: news

Maintenance Peanut Oral Immunotherapy Effective for Preschoolers
TUESDAY, Dec. 15, 2020 -- Maintenance oral immunotherapy is effective at one year for reducing peanut allergies in preschoolers, according to a study published online Dec. 2 in the Journal of Allergy and Clinical Immunology: In Practice. Lianne... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 15, 2020 Category: Pharmaceuticals Source Type: news

Top 10 Mesothelioma and Asbestos News Stories of 2020
Growing allegations of asbestos-contaminated talc in various consumer products, coupled with historic approval of a new treatment for pleural mesothelioma, made 2020 a year filled with both anxiety and hope. Johnson & Johnson stopped selling its iconic baby powder in May after being hit by thousands of lawsuits contending its talc-based product was causing various cancers, including ovarian cancer and malignant mesothelioma. The U.S. Food and Drug Administration approved the immunotherapy combination of Opdivo and Yervoy in October, the first new drug regimen approved for first-line treatment of unresectable disease in...
Source: Asbestos and Mesothelioma News - December 15, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Immune cell that drives breast cancer could be effective target in novel immunotherapies
(Virginia Commonwealth University) VCU Massey Cancer Center researcher Paula Bos, Ph.D., identified a type of immune cells that acts as a major driver of breast cancer growth by preventing the accumulation of a specific protein that induces anti-tumor responses. This new knowledge could be utilized for the development of novel immunotherapeutic approaches to treat the disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 15, 2020 Category: International Medicine & Public Health Source Type: news

Molecule holds promise to reprogram white blood cells for better cancer treatment
(Medical College of Georgia at Augusta University) Cancer immunotherapy using " designer " immune cells has revolutionized cancer treatment. In this type of therapy, T cells, a type of white blood cell, are collected from a patient's blood and genetically engineered to produce T cells carrying a synthetic molecule termed chimeric antigen receptor (CAR) that enables T cells to recognize and destroy cancer cells. Then these genetically modified CAR T cells are expanded and infused back to the patient. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - December 14, 2020 Category: Biology Source Type: news

Drugs create balancing act for patients with non-small cell lung cancer
(Johns Hopkins Medicine) Johns Hopkins Kimmel Cancer Center and Bloomberg~Kimmel Institute for Cancer Immunotherapy researchers identified a correlation between multisystem immune-related adverse events and improved rates of survival. This new information will be helpful in discussing with patients the spectrum of immune side effects that may occur from immunotherapy and the implications for their future. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 14, 2020 Category: International Medicine & Public Health Source Type: news

New analysis method for predicting the risks and effects of immunotherapy
(Uppsala University) In a new study, researchers at Uppsala University have been able to show differences in how Rituximab, a monoclonal antibody drug, interacts with the blood of healthy individuals compared to patients with chronic lymphocytic leukaemia. This has awakened hopes that this analysis method could pave the way for important breakthroughs in immunotherapy research and treatment. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 11, 2020 Category: International Medicine & Public Health Source Type: news

Immunotherapy improves responses w/o reducing quality of life in early breast cancer
(Dana-Farber Cancer Institute) Adding an immune checkpoint inhibitor to the standard chemotherapy regimen for patients with early-stage breast cancer places no greater burden on patients' ability to perform day-to-day activities than chemotherapy alone, new research by Dana-Farber/Brigham and Women's Cancer Center investigators shows. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 10, 2020 Category: Cancer & Oncology Source Type: news

Phase 1 trial assesses whether fecal microbiota transplant impacts cancer patients resistant to immu
(American Association for the Advancement of Science) In one of the first in-human studies to investigate whether modifying the gut microbiome by a fecal microbiota transplant could make cancer immunotherapy more effective, researchers analyzing this in ten cancer patients with refractory melanoma suggest the treatment can improve patient outcomes. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 10, 2020 Category: Cancer & Oncology Source Type: news

The immunomodulatory activity of a drug would improve the efficacy of immunotherapy in breast cancer
(Centro Nacional de Investigaciones Oncol ó gicas (CNIO)) * The team of Eva Gonz á lez-Suarez, from the CNIO and IDIBELL, and the team of Christos Sotiriou, from the Jules Bordet Institute, demonstrate that a drug already used to treat osteoporosis promotes the infiltration of immune cells in breast tumours* These findings propose a new target to increase the antitumor immune response and make breast cancer more sensitive to immunotherapy (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 10, 2020 Category: Cancer & Oncology Source Type: news

Despite COVID-19 pandemic first patient undergoes new personalized immunotherapy
(University of California - San Diego) Bernard Thurman was referred to a personalized cancer therapy trial at Moores Cancer Center at UC San Diego Health, a collaboration with the La Jolla Institute for Immunology, the trial employs a patient's immune cells -- specifically tumor infiltrating lymphocytes (TIL) -- to destroy cancer cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 10, 2020 Category: Cancer & Oncology Source Type: news

Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer
Adoptive T cell therapy (ACT) using ex vivo–expanded autologous tumor-infiltrating lymphocytes (TILs) can mediate complete regression of certain human cancers. The impact of TIL phenotypes on clinical success of TIL-ACT is currently unclear. Using high-dimensional analysis of human ACT products, we identified a memory-progenitor CD39-negative stem-like phenotype (CD39–CD69–) associated with complete cancer regression and TIL persistence and a terminally differentiated CD39-positive state (CD39+CD69+) associated with poor TIL persistence. Most antitumor neoantigen-reactive TILs were found in the differenti...
Source: ScienceNOW - December 10, 2020 Category: Science Authors: Krishna, S., Lowery, F. J., Copeland, A. R., Bahadiroglu, E., Mukherjee, R., Jia, L., Anibal, J. T., Sachs, A., Adebola, S. O., Gurusamy, D., Yu, Z., Hill, V., Gartner, J. J., Li, Y. F., Parkhurst, M., Paria, B., Kvistborg, P., Kelly, M. C., Goff, S. L., Tags: Immunology, Medicine, Diseases reports Source Type: news

Obesity impairs immune cell function, accelerates tumor growth
(Harvard Medical School) New study in mice finds that a high-fat diet allows cancer cells to outcompete immune cells for fuel, impairing immune function and accelerating tumor growth. Cancer cells do so by rewiring their metabolisms to increase fat consumption. Blocking this rewiring enhances anti-tumor immunity. Findings suggest new strategies to target cancer metabolism, improve immunotherapies. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 9, 2020 Category: Cancer & Oncology Source Type: news